A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Epcoritamab (Primary) ; Bendamustine; Gemcitabine; Oxaliplatin; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms EPCORE DLBCL-1; EPCORE&TRADE
- Sponsors Genmab
- 23 Jul 2024 According to an AbbVie media release, EPKINLY has also received a positive recommendation for the same indication from INESSS to list it in Quebec contingent on submission and reassessment of phase III clinical data once available.
- 04 Aug 2023 Planned primary completion date changed from 1 Apr 2028 to 1 Dec 2024.
- 22 Jun 2023 According to a Genmab media release, AbbVie will continue to pursue regulatory submissions for epcoritamab across international markets excluding the U.S. and Japan throughout the year.